A new systems approach to diseased states and wellness result in a new branch in the healthcare services, namely, personalized and precision medicine (PPM). The concept of PPM is becoming increasingly relevant for cancer treatment, moving from the ‘one-size-fits-all’ standard therapy to a more personalized scheme guided by molecular diagnostics.
A comprehensive molecular tumor analysis integrating a combination of NGS methods offers the best chance for personalizing cancer care, enlarging the scope of therapy choices and offering potential new options for challenging cases, for instance metastatic tumors, rare cancer types, and cancers of unknown primary. Cutting-edge bioinformatics pipelines integrate the multiple data levels to construct Big Data and Data Sets and to generate a personalized tumor report. Though the panel approach helps to orientate therapy choices for particular cancer types, many “hard to treat” tumors remain in need of more effective diagnostic solutions.
A consolidated team of molecular pathologists, IT experts and cancer practitioners of the next step generation are becoming to play a crucial role in developing and implementing OMICS-based profiling tests in practice and communicate the results and their relevance with clinicians. Such approach is considered to be of utmost importance for successfully translating the latest advancements into a benefit to patients, illustrating a generation of the “next-generation cancer pathologists, cancer-related practitioners and oncologists globally”.
Along with the above-mentioned, theranostics is an innovative concept of personalized therapy that focuses on both the accurate selection of patients and providing them with targeted radioligand cancer therapy to improve their prognosis. As you see, the integrated value chain of PPM-related oncology tools equips theranostics programs with state-of-the-art solutions at every step of the theranostics care pathway.